Callitas Health Inc. (CNSX:LILY)

Callitas Health Inc. (CNSX:LILY)


Share Price
$ 0.11
Change
0.005 (5.00 %)
Market Cap
$3.45 m
Proactive Investors - Run By Investors For Investors

Callitas Health Inc.

Founded on Midwest values, our Cincinnati-based company is people-focused, always looking for ways to benefit our customers, shareholders, and employees. Our company was built on strong work ethic, honesty, and a desire to help others.
Our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit...

EPIC: LILY
Market: CSE:LILY
OTCQB:MPHMF
52-week High/Low: C$0.375 / C$0.090
Sector: Pharma & Biotech
Market Cap: C$3.45M
Website: www.callitas.com
col 3
col 4
col 5
col 6

Big picture - Why invest in Callitas Health Inc.


Callitas Health Inc. Snapshot

Our Mission
Always looking forward, we continually stay up-to-date on developing news and trends in the pharmaceutical industry. We are always looking for products, drugs and technologies that will benefit our customers. As a publicly-traded company, our shareholders are also important to us. Our goal is to make decisions that directly benefit them and show our appreciation for their support in our company.
As a company with its roots in female health and wellness, we are committed to delivering breakthrough products and services that truly improve daily living. Our logo, the beautiful and strong Calla Lily, represents our mission and goals.

To Conceive

Based on the science from the 2010 Nobel Prize in Medicine for In-Vitro Fertilization and Sperm Capacitation, ToConceive is a fertility enhancing moisturizer. It is clinically proven to increase a woman’s own natural conception lubrication, called transudate, to aid in conception. This increase in natural transudate is required for sperm capacitation, the process that allows the sperm to travel the required distance to the ovum and have the appropriate chemical makeup for successful conception to occur. ToConceive is supported by FDA 510K clearance and is protected by four USPTO patents.

  • FDA cleared and based on the 2010 Nobel Prize for Medicine
  • All-natural and paraben-free
  • Promotes sperm capacitation, a key component to conception

For more inormation, please click here

 

C-103 Reformulated Orlistat

The reformulation of Orlistat, C-103 maintains its proven efficacy while minimizing or eliminating undesirable side effects. Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter). Safe and effective, the C-103 reformulation addresses the adverse side effects reported by over 90% of Orlistat users. Orlistat is not an amphetamine, not systemically absorbed, and does not affect the central nervous system. It is also the only FDA-approved weight loss drug for adolescent patients, ages 12-18.

  • Addresses 90% of the negative side effects of orlistat
  • FDA-approved for over-the-counter use
  • Safe alternative for weight loss

For more information, please click here

 

Extrinsa

Created to address the lack of female sexual dysfunction solutions, Extrinsa focuses on women with orgasm and arousal difficulties. The topical, local, and non-systemic product is also non-hormonal and does not affect the central nervous system. Callitas recently received a trademark from the US Patent Office and is working with Camargo Pharmaceutical Services to bring the product to market.

  • Well-tolerated by most women
  • Safe, natural and effective
  • Addresses major need for a female sexual dysfunction product

For more information, please click here

James Thompson
Chief Operating Officer

After earning a Bachelor’s of Science in Biomedical Engineering and a double major in Finance from Washington University in St. Louis, MO, James went on to earn an Executive MBA from Xavier University in Cincinnati, OH.
Along with holding multiple granted and pending patent applications, he has managed the development, testing, production and distribution of all types of healthcare products worldwide over the last 18 plus years. James was previously the Managing Member at 40 J’s LLC, the private healthcare development corporation whose primary assets were acquired in early 2017 by Callitas Therapeutics.

Dr. Laura Berman
Chief Health Advisor

Dr. Berman is a world-renowned sex and relationship educator, researcher and therapist, as well as TV, radio and internet host, presenting the weeknight radio program “Uncovered with Dr. Laura Berman.” She’s a New York Times best-selling author on sexual health and pleasure. Dr. Berman also acts as assistant clinical professor of OBGYN and psychiatry at the Feinberg School of Medicine at Northwestern University in Chicago.

D. Richard Skeith, BA/JD
Director

BA (Hons) in Economics, University of Alberta; JD Faculty of Law, University of Alberta
Practicing lawyer with specialized focus on publicly traded companies

Broad experience as an Officer or Director of multiple public companies in sectors including pharmaceuticals, mining, oil and gas, and real estate

Dr. Ron Thompson, M.D.
Inventor & Staff Medical Expert

Improving patient outcomes has been the driving force behind all of Dr. Thompson’s inventions, developments and patient care in the last 40 years. He has been a member of the American Fertility Society since 1988, and is also a Fellow of the American College of Obstetricians and Gynecologists and a Diplomat of American Board of Obstetrics and Gynecology.
Dr. Thompson holds 40 issued U.S. medical device and drug patents, including two pending U.S. and international patent applications. He also has two additional U.S. and international patent applications in process that support C-103’s development and exclusivity.

His extensive career extends even further, with over a decade worth of pharmaceutical and medical device consulting. Dr. Thompson has worked with UBS, Genzyme Corporation, Amgen Corporation, Cephalon Corporation, Ethicon Incorporated (Johnson and Johnson) and Proctor and Gamble Pharmaceuticals.

Joshua Maurice
Director of Sales and Marketing

Bringing over 15 years of consumer goods experience to the Callitas team, Joshua Maurice has worked in a variety of areas ranging from women’s health care to dietary supplements. He has overseen and coordinated multi-million dollar marketing campaigns, and has successfully integrated products into some of the largest retailers in the country.
With brand and private label background expertise, as well as direct response marketing experience, Joshua helps Callitas continue to innovate within the evolving marketplace.

Lindsey M. Thompson
Director of Brand Management

Before joining Callitas, Lindsey managed the marketing and social media for two top-rated, multi-million Indianapolis real estate agents and played a key role on Guest Hook’s copywriting team. Lindsey is a graduate of E.W. Scripps School of Journalism at Ohio University, with a degree in journalism/public relations, plus minors in business and sociology.
She brings more than 10 years of experience to Callitas in marketing, public relations, social media, event planning, and writing. Her experience spans numerous industries including real estate, health and wellness, personal finance, business, travel, religious, fine arts, and non-profit and community organizations.

Dr. Christopher Andrews, M.D., MSc, FRCPC
Director

Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN
Specialist in stomach disorders and physiology, with advanced training in gastrointestinal motility and function

Master’s Degree in Clinical Health Research from the Mayo Clinic

Kim E. Whittemore, B.S.
Management Consultant

University of Pennsylvania International Relations graduate, completed MIT executive courses in Computer Science and has an advanced certificate in digital marketing
Held senior executive positions with DecisionOne Corporation, Verizon and AT&T after beginning her career at the National Security Agency (NSA)

Vast experience in the fields of digital health, wearable tech and women’s health, and works with clients on business strategy and digital marketing through her management consulting practice

William A. Rodgers, Jr., B.S.
President and CEO of Four 12 Solutions

Senior executive management background with both publicly traded and private equity backed businesses. Key expertise with acquisition and start up activities, leading the expansion of businesses and new market entry.
Held several Senior Executive level positions at Fortune 150 Corporations, including Waste Management, Inc., Johnson Controls, Inc. and EMCOR Group.

Former President and Chief Executive Officer for GoodCents Holdings, Inc. and currently CEO and President of Four 12 Solutions assisting companies achieve aggressive growth objectives and enhancing operational effectiveness.

CONTACT US

1.859.868.3131
[email protected]

187 Pavilion Parkway
Suite 200
Newport, Kentucky 41071

 

INVESTMENT OPPORTUNITIES

[email protected]

 

MEDIA & PRESS INQUIRIES

[email protected]

 

PARTNERING OPPORTUNITIES

[email protected]

PRODUCT INQUIRIES

[email protected]

Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use